Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 10/20 | 0.44 |
| ▸ | TK1 | P04183 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21396414 | 0.82 | PNP (0.47) | PNPTK1CYP3A4MAPTUSP2 | |
| SCHEMBL23921068 | 0.79 | HSP90B1 (0.48) | PNPTK1CYP3A4MAPTXDH | |
| SCHEMBL21396398 | 0.78 | PNP (0.52) | PNPTK1CYP3A4MAPTUSP2 | |
| SCHEMBL21396375 | 0.77 | CYP3A4 (0.47) | PNPTK1CYP3A4MAPTUSP2 | |
| SCHEMBL23921138 | 0.77 | CYP3A4 (0.46) | PNPTK1CYP3A4MAPTUSP2 | |
| SCHEMBL23921113 | 0.76 | PNP (0.50) | PNPTK1CYP3A4MAPTUSP2 | |
| SCHEMBL23921101 | 0.76 | PNP (0.46) | PNPTK1CYP3A4MAPTUSP2 | |
| SCHEMBL23920795 | 0.76 | PNP (0.52) | PNPTK1USP2TSHREDNRA | |
| SCHEMBL23920991 | 0.76 | PNP (0.53) | PNPTK1CYP3A4MAPTUSP2 | |
| SCHEMBL23921096 | 0.76 | CYP3A4 (0.46) | PNPTK1CYP3A4MAPTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20210317156-A1 | NEW POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PRKAG3 | PNP 111/4885TK1 460/4885CYP3A4 3988/4885 |
| US-20210317156-A1 | NEW POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PDE7A | PNP 106/4885TK1 536/4885CYP3A4 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.